Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity.

Kitamura N, Murata S, Ueki T, Mekata E, Reilly RT, Jaffee EM, Tani T.

Int J Cancer. 2009 Aug 1;125(3):630-8. doi: 10.1002/ijc.24435.

2.

An immunotolerant HER-2/neu transgenic mouse model of metastatic breast cancer.

Song H, Shahverdi K, Huso DL, Wang Y, Fox JJ, Hobbs RF, Gimi B, Gabrielson KL, Pomper MG, Tsui BM, Bhujwalla Z, Reilly RT, Sgouros G.

Clin Cancer Res. 2008 Oct 1;14(19):6116-24. doi: 10.1158/1078-0432.CCR-07-4672.

3.

213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model.

Song H, Shahverdi K, Huso DL, Esaias C, Fox J, Liedy A, Zhang Z, Reilly RT, Apostolidis C, Morgenstern A, Sgouros G.

Cancer Res. 2008 May 15;68(10):3873-80. doi: 10.1158/0008-5472.CAN-07-6308. Erratum in: Cancer Res. 2008 Jun 15;68(12):4958. Liedy, Allison [corrected to Liedy, Alyson].

4.

Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs.

Kim PS, Armstrong TD, Song H, Wolpoe ME, Weiss V, Manning EA, Huang LQ, Murata S, Sgouros G, Emens LA, Reilly RT, Jaffee EM.

J Clin Invest. 2008 May;118(5):1700-11. doi: 10.1172/JCI34333.

5.

Ductal access for prevention and therapy of mammary tumors.

Murata S, Kominsky SL, Vali M, Zhang Z, Garrett-Mayer E, Korz D, Huso D, Baker SD, Barber J, Jaffee E, Reilly RT, Sukumar S.

Cancer Res. 2006 Jan 15;66(2):638-45.

6.

OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.

Murata S, Ladle BH, Kim PS, Lutz ER, Wolpoe ME, Ivie SE, Smith HM, Armstrong TD, Emens LA, Jaffee EM, Reilly RT.

J Immunol. 2006 Jan 15;176(2):974-83.

7.

Cancer vaccines in combination with multimodality therapy.

Emens LA, Reilly RT, Jaffee EM.

Cancer Treat Res. 2005;123:227-45. Review. No abstract available.

PMID:
16211873
8.

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response.

Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, Bieler JG, Emens LA, Reilly RT, Jaffee EM.

J Exp Med. 2005 May 16;201(10):1591-602. Epub 2005 May 9.

9.

Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity.

Emens LA, Reilly RT, Jaffee EM.

Endocr Relat Cancer. 2005 Mar;12(1):1-17. Review.

10.

Augmenting the potency of breast cancer vaccines: combined modality immunotherapy.

Emens LA, Reilly RT, Jaffee EM.

Breast Dis. 2004;20:13-24. Review.

PMID:
15687703
11.

Sasa health exerts a protective effect on Her2/NeuN mammary tumorigenesis.

Ren M, Reilly RT, Sacchi N.

Anticancer Res. 2004 Sep-Oct;24(5A):2879-84.

12.

Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.

Dakappagari NK, Lute KD, Rawale S, Steele JT, Allen SD, Phillips G, Reilly RT, Kaumaya PT.

J Biol Chem. 2005 Jan 7;280(1):54-63. Epub 2004 Oct 26.

13.

A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin.

Emens LA, Armstrong D, Biedrzycki B, Davidson N, Davis-Sproul J, Fetting J, Jaffee E, Onners B, Piantadosi S, Reilly RT, Stearns V, Tartakovsky I, Visvanathan K, Wolff A.

Hum Gene Ther. 2004 Mar;15(3):313-37. No abstract available.

PMID:
15018740
14.

BNP-7787 (BioNumerik/Baxter Oncology/Grelan).

Reilly RT.

IDrugs. 2004 Jan;7(1):64-9. Review.

PMID:
14730469
15.

Proper costimulation of tumor-reactive T lymphocytes may provide a key to unlock their antitumor activity.

Reilly RT.

Cancer Biol Ther. 2003 Sep-Oct;2(5):587-8. No abstract available.

PMID:
14614332
17.

Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice.

Ercolini AM, Machiels JP, Chen YC, Slansky JE, Giedlen M, Reilly RT, Jaffee EM.

J Immunol. 2003 Apr 15;170(8):4273-80.

18.

Cytokine gene-modified cell-based cancer vaccines.

Reilly RT, Machiels JP, Emens LA, Jaffee EM.

Methods Mol Med. 2002;69:233-57. Review. No abstract available.

PMID:
11987781
19.

Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer?

Reilly RT, Emens LA, Jaffee EM.

Curr Opin Investig Drugs. 2001 Jan;2(1):133-5. Review.

PMID:
11527005
20.
21.

Chemotherapy: friend or foe to cancer vaccines?

Emens LA, Machiels JP, Reilly RT, Jaffee EM.

Curr Opin Mol Ther. 2001 Feb;3(1):77-84. Review.

PMID:
11249735
22.

The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.

Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D, Jaffee EM.

Cancer Res. 2001 Feb 1;61(3):880-3.

23.

HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.

Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, Okoye FI, Muller WJ, Dixon KH, Jaffee EM.

Cancer Res. 2000 Jul 1;60(13):3569-76.

24.

Functional effects of amino acid substitutions at residue 33 of human thymidylate synthase.

Reilly RT, Forsthoefel AM, Berger FG.

Arch Biochem Biophys. 1997 Jun 15;342(2):338-43.

PMID:
9186496
25.

Biphasic binding of 5-fluoro-2'-deoxyuridylate to human thymidylate synthase.

Reilly RT, Barbour KW, Dunlap RB, Berger FG.

Mol Pharmacol. 1995 Jul;48(1):72-9.

PMID:
7623777
26.

Phosphorus-31 nuclear magnetic resonance studies of complexes of thymidylate synthase.

Connick TJ, Reilly RT, Dunlap RB, Ellis PD.

Biochim Biophys Acta. 1994 Sep 21;1208(1):118-26.

PMID:
8086425
27.
28.

Phlorizin enhancement of memory in rats and mice.

Hall JL, Reilly RT, Cottrill KL, Stone WS, Gold PE.

Pharmacol Biochem Behav. 1992 Feb;41(2):295-9.

PMID:
1574518
29.

Cost savings achieved through cephalosporin use review and restriction.

Dzierba SH, Reilly RT, Caselnova DA 3rd.

Am J Hosp Pharm. 1986 Sep;43(9):2194-7.

PMID:
3766571
30.

Cost comparison of two systems for intermittent intravenous administration of small-volume injections.

Reilly RT, Strand LM, Bair JN.

Am J Hosp Pharm. 1985 Feb;42(2):323-8.

PMID:
3976678

Supplemental Content

Loading ...
Support Center